Trofinetide<\/a> is a synthetic glycine-proline-glutamic acid (GPE) tripeptide analogue derived from the N-terminal sequence of insulin-like growth factor 1 (IGF-1). It is primarily used to treat Rett syndrome (RTT), a rare inherited neurodevelopmental disorder that primarily affects women and is usually caused by mutations in the MECP2 gene.<\/p>\n\n\n\n Trofinetide works by reducing neuroinflammation and supporting synaptic function. Its mechanism of action includes enhancing synaptic activity, restoring synaptic structure, inhibiting the effects of inflammatory compounds in the brain, increasing antioxidant responses, reducing injury-induced apoptosis, and increasing the presence of IGF-1 in the central nervous system. In addition, Trofinetide has also been found to be able to inhibit the production of inflammatory cytokines and inhibit the overactivation of microglia and astrocytes.<\/p>\n\n\n Trofinetide is the first FDA-approved drug for the treatment of Rett syndrome in adults and children 2 years of age and older. In clinical trials, Trofinetide has shown significant improvements in the core symptoms of Rett syndrome, such as communication, behavior, and motor function. However, although its efficacy has been validated, its exact mechanism of action needs further research. Trofinetide is an innovative therapy for Rett syndrome that improves the neurological function and structure of patients through multiple mechanisms, bringing new hope to this disease that has long lacked effective treatments. <\/p>\n\n\n\n Rett syndrome is a rare genetic disorder that affects psychomotor development in children, mainly due to mutations in the methyl-binding protein 2 (MECP2) gene on the X chromosome. Rett syndrome is a neurodevelopmental disorder that affects female children and is characterized by loss of verbal communication, stereotyped hand movements, seizures, and behavioral problems. Trofinetide, through its synthetic glycine-proline-glutamate analogue properties, aims to improve the adverse pharmacokinetic profile of naturally occurring GPE in the brain, thereby positively affecting the symptoms of patients with Rett syndrome.<\/p>\n\n\n![\"Diagram](\"https:\/\/www.creative-peptides.com\/blog\/wp-content\/uploads\/2024\/11\/Chemical-structure-of-Trofinetide-A-and-GPE-B.jpg\")
<\/a>Trofinetide <\/strong>in <\/strong>Rett Syndrome<\/strong><\/strong><\/h2>\n\n\n\n
![\"General](\"https:\/\/www.creative-peptides.com\/blog\/wp-content\/uploads\/2024\/11\/General-aspects-of-Rett-Syndrome.jpg\")
<\/a>![\"Diseases](\"https:\/\/www.creative-peptides.com\/blog\/wp-content\/uploads\/2024\/11\/Function-and-disease-associated-with-MECP2-mutations.jpg\")
<\/a>